<DOC>
	<DOCNO>NCT02855268</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , multi-center , Phase 2 study conduct subject Alport syndrome multiple investigative center .</brief_summary>
	<brief_title>Study Weekly RG-012 Injections Patients With Alport Syndrome</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , multi-center , Phase 2 study conduct subject Alport syndrome multiple investigative centers.To meet GFR enrollment criterion , subject must eGFR 45 90 ml/min/1.73 m2 first screen visit demonstrate decline eGFR screen period . Subjects may screen enrollment directly study participation RG012-01 ATHENA Natural History Study . For subject participate ATHENA Study , genotype , demographic , prior/concomitant medication , medical history , family history data study may use satisfy entry criterion current study . Data obtain ATHENA Study clinical laboratory test ( eGFR ) may use screen data present study obtain within 4 week prior baseline . Physical examination result ATHENA study may use screen data present study obtain within 12 week prior baseline . Active Treatment Period - Eligible subject randomize 1:1:1 ratio receive weekly subcutaneous ( SC ) injections RG-012 110 mg , RG-012 220 mg , placebo 24 week . Subjects take angiotensin convert enzyme ( ACE ) inhibitor angiotensin II receptor blocker ( ARBs ) require maintain agent stable dose regimen duration active treatment period . All concomitant medication also maintain stable dose regimen study . Follow-up Period - Subjects complete 24 week treatment eligible screen enrollment extension study subject receive active treatment . Subjects enter extension safety follow-up home visit 4 week ( Week 28 ) end active treatment period safety follow-up clinic visit 12 week ( Week 36 ) end active treatment period .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Nephritis , Hereditary</mesh_term>
	<criteria>1 . Male female subject age 18 65 year ( inclusive ) 2 . Confirmed diagnosis Alport syndrome ( clinical , histopathologic , and/or genetic diagnosis ) 3. eGFR criterion must meet 4 . Proteinuria ≥500 mg protein/g creatinine initial screen baseline visit 5 . On stable dose regimen ACE inhibitor and/or ARB ≥30 day prior screen ( unless unable tolerate either ACE inhibitor ARB ) 1 . Causes chronic kidney disease aside Alport syndrome ( include , limited , diabetic nephropathy , hypertensive nephropathy , lupus , IgA nephropathy ) 2 . ESRD evidence ongoing dialysis therapy history renal transplantation 3 . Any condition circumstance , opinion Investigator , may make subject unlikely complete study comply study procedures requirement , may pose risk subject 's safety wellbeing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Kidney disease , nephritis</keyword>
</DOC>